Currency In USD
| Previous Close | 0.41 |
| Open | 0.42 |
| Day High | 0.42 |
| Day Low | 0.37 |
| 52-Week High | 1.3 |
| 52-Week Low | 0.37 |
| Volume | 356,468 |
| Average Volume | 1.09M |
| Market Cap | 37.78M |
| PE | -1.39 |
| EPS | -0.27 |
| Moving Average 50 Days | 0.6 |
| Moving Average 200 Days | 0.84 |
| Change | -0.04 |
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
GlobeNewswire Inc.
Mar 02, 2026 2:00 PM GMT
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirm
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
GlobeNewswire Inc.
Feb 24, 2026 2:00 PM GMT
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution SAN DIEGO, Feb. 24, 2026 (GLOBE
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
GlobeNewswire Inc.
Feb 04, 2026 1:50 PM GMT
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with interim data expected by the end of